2024
IMPLEMENTING ADHERENCE TO SGLT2I AND GLP1RA IN PATIENTS WITH CARDIOVASCULAR DISEASE: FINDINGS FROM A PHARMACIST-DRIVEN CARDIODIABETES CLINIC PROGRAM
Lee K, Ikram M, Mishkel G, Ng E, Krupa E, Zahvolskyy L, Davidson D, Gordon R, Billings L, Sarav M, Block R, Erwin J, Qamar A. IMPLEMENTING ADHERENCE TO SGLT2I AND GLP1RA IN PATIENTS WITH CARDIOVASCULAR DISEASE: FINDINGS FROM A PHARMACIST-DRIVEN CARDIODIABETES CLINIC PROGRAM. Journal Of The American College Of Cardiology 2024, 83: 1938. DOI: 10.1016/s0735-1097(24)03928-7.Peer-Reviewed Original Research
2023
Peritoneal Dialysis-Related Peritonitis With Acinetobacter Pittii: A Case Report
Bajaj T, Ismail N, Trivedi A, Sarav M. Peritoneal Dialysis-Related Peritonitis With Acinetobacter Pittii: A Case Report. Journal Of Investigative Medicine High Impact Case Reports 2023, 11: 23247096221148264. PMID: 36624661, PMCID: PMC9834918, DOI: 10.1177/23247096221148264.Peer-Reviewed Original ResearchConceptsPeritoneal dialysis (PD)-related peritonitisPeritoneal dialysis-related peritonitisSensitive to ceftazidimeEnd-stage renal diseaseNidus of infectionIntraperitoneal antibioticsPD catheterWorsening infectionCase reportSevere infectionsRenal diseasePeritonitisInfectionAcinetobacter pittiiSterile techniqueYoung menHand hygieneComplex groupGroup of organismsCeftazidimeComplex group of organismsCatheterPatientsNidusReports
2022
Peritoneal Dialysis Peritonitis With Acinetobacter pittii
Bajaj T, Ismail N, Trivedi A, Sarav M. Peritoneal Dialysis Peritonitis With Acinetobacter pittii. Journal Of The American Society Of Nephrology 2022, 33: 455-455. DOI: 10.1681/asn.20223311s1455c.Peer-Reviewed Original ResearchResults from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy
Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Rovin B, Fragale G, Karl A, Losisolo P, Trimarchi H, Hoyos I, Lampo M, Monkowski M, De La Fuente J, Alvarez M, Stoppa D, Chiurchiu C, Novoa P, Orias M, Barron M, Giotto A, Arriola M, Cassini E, Maldonado R, Dionisi M, Ryan J, Toussaint N, Luxton G, Peh C, Levidiotis V, Francis R, Phoon R, Fedosiuk E, Toropilov D, Yakubtsevich R, Mikhailova E, Bovy C, Demoulin N, Hougardy J, Maes B, Speeckaert M, Laurin L, Barbour S, Masse M, Hladunewich M, Reich H, Cournoyer S, Tennankore K, Barbour S, Lv J, Liu Z, Wang C, Li S, Luo Q, Ni Z, Yan T, Fu P, Cheng H, Liu B, Lu W, Wang J, Chen Q, Wang D, Xiong Z, Chen M, Xu Y, Wei J, Pai P, Chen L, Rehorova J, Maixnerova D, Safranek R, Rychlik I, Hruby M, Makela S, Vaaraniemi K, Ortiz F, Alamartine E, Daroux M, Cartery C, Vrtovsnik F, Serre J, Stamellou E, Vielhauer V, Hugo C, Budde K, Otte B, Nitschke M, Ntounousi E, Boletis I, Papagianni A, Goumenos D, Stylianou K, Zermpala S, Esposito C, Cozzolino M, Viganò S, Gesualdo L, Nowicki M, Stompor T, Kurnatowska I, Kim S, Kim Y, Na K, Kim D, Kim S, Porras L, Garcia E, Pamplona I, Segarra A, Goicoechea M, Fellstrom B, Lundberg S, Hemmingsson P, Guron G, Sandell A, Chen C, Tokgoz B, Duman S, Altiparmak M, Ergul M, Maxwell P, Mark P, McCafferty K, Khwaja A, Cheung C, Hall M, Power A, Kanigicherla D, Baker R, Moriarty J, Mohamed A, Aiello J, Canetta P, Ayoub I, Robinson D, Thakar S, Mottl A, Sachmechi I, Fischbach B, Singh H, Mulhern J, Kamal F, Linfert D, Rizk D, Wadhwani S, Sarav M, Campbell K, Coppock G, Luciano R, Sedor J, Avasare R, Lau W. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney International 2022, 103: 391-402. PMID: 36270561, DOI: 10.1016/j.kint.2022.09.017.Peer-Reviewed Original ResearchConceptsTreatment-emergent adverse eventsSecondary efficacy outcomesTwo-part trialGlomerular filtration rateMonths of treatmentPart AEGFR preservationOral budesonidePrimary IgANEfficacy outcomesNephropathy TrialPrimary endpointAdult patientsAdverse eventsCreatinine ratioIgA nephropathyKidney failureUrine proteinFiltration ratePlaceboTherapeutic potentialPrimary immunoglobulinUPCRMonthsTrials
2020
Trastuzumab-Induced Thrombocytopenia Correlated by Drug-Dependent Platelet Antibodies.
Sullivan K, Kaminer L, Grinblatt D, Campbell N, Nocon C, Harper A, Kang J, Sarav M, Curtis B, Brockstein B. Trastuzumab-Induced Thrombocytopenia Correlated by Drug-Dependent Platelet Antibodies. JCO Oncology Practice 2020, 17: 153-155. PMID: 33270522, DOI: 10.1200/op.20.00734.Peer-Reviewed Original ResearchAcute Kidney Injury Incidence in Hospitalized Patients and Implications for Nutrition Support
Meyer D, Mohan A, Subev E, Sarav M, Sturgill D. Acute Kidney Injury Incidence in Hospitalized Patients and Implications for Nutrition Support. Nutrition In Clinical Practice 2020, 35: 987-1000. PMID: 33140897, DOI: 10.1002/ncp.10595.Peer-Reviewed Original ResearchConceptsAcute kidney injuryAdult patientsRates of acute kidney injuryHospitalized patientsAcute kidney injury incidenceManagement of acute kidney injuryMultiple nutritional problemsAdequate nutritional supportHospitalized adult patientsKidney injuryNutritional supportPatientsNutritional problemsIncidenceInjury incidence
2019
Refeeding Syndrome in the Critically Ill: a Literature Review and Clinician’s Guide
McKnight C, Newberry C, Sarav M, Martindale R, Hurt R, Daley B. Refeeding Syndrome in the Critically Ill: a Literature Review and Clinician’s Guide. Current Gastroenterology Reports 2019, 21: 58. PMID: 31758276, DOI: 10.1007/s11894-019-0724-3.Peer-Reviewed Original ResearchConceptsRefeeding syndromeCritically ill patientsNational Institute for Health and Clinical Excellence criteriaAssessment toolDefinition of RFSNutrition care planModerate to severe malnutritionClinical assessment toolIll patientsCritically ill patient populationNutritional assessment toolManagement of refeeding syndromeDecrease complication ratesCare planningIll patient populationLife-threatening conditionMethods of diagnosisMetabolic teamComplication rateGastrointestinal complicationsClinician's GuideDecrease morbiditySevere malnutritionNutritional supportElectrolyte imbalanceKetogenic Diet: from the Historical Records to Use in Elite Athletes
Kaspar M, Austin K, Huecker M, Sarav M. Ketogenic Diet: from the Historical Records to Use in Elite Athletes. Current Nutrition Reports 2019, 8: 340-346. PMID: 31713719, DOI: 10.1007/s13668-019-00294-0.Peer-Reviewed Original ResearchConceptsImprove body compositionHuman athletic performanceLow-carbohydrate/high-fatElite athletesStrength activitiesAthletic performanceOutcome measuresBody compositionFindingsMultiple studiesAthletesReview studiesSystem of exercisesLow-carbohydrateMultiple studiesLiterature/evidenceOutcomesExerciseEnduranceInterventionSportsAvailable dataLCKDImpaired performanceProtein Supplementation in Sport: Source, Timing, and Intended Benefits
Huecker M, Sarav M, Pearlman M, Laster J. Protein Supplementation in Sport: Source, Timing, and Intended Benefits. Current Nutrition Reports 2019, 8: 382-396. PMID: 31713177, DOI: 10.1007/s13668-019-00293-1.Peer-Reviewed Original ResearchConceptsBenefit purposesSportsMulti-billion-dollar marketClinically relevant outcomesDietary protein consumptionAthletesHealthy subjectsReviewThe purposeHigh-protein dietMarketEffects of protein supplementationLong-term implicationsShort-termExercise activitiesRelevant outcomesNutrient timingOptimal dietary proteinProtein consumptionSupplement formImplicationsProtein supplementationSupplementationOutcomesPurposesDietary protein
2018
Histiocytic Glomerulopathy as a Manifestation of Macrophage Activation Syndrome
Kaur A, Diaz-Perez J, Weiner R, Cibull T, Sarav M, Victor T. Histiocytic Glomerulopathy as a Manifestation of Macrophage Activation Syndrome. American Journal Of Clinical Pathology 2018, 150: s12-s12. DOI: 10.1093/ajcp/aqy090.029.Peer-Reviewed Original ResearchMacrophage activation syndromeAcute kidney injuryHemophagocytic lymphohistiocytosisMacrophage hyperactivationActivation syndromeEndocapillary hypercellularityManifestation of macrophage activation syndromeCases of macrophage activation syndromeFeatures of macrophage activation syndromeWorsening acute kidney injurySignificant postpartum hemorrhageLow complement levelsCytotoxic T lymphocytesElevated lipase levelsExcessive macrophage activationNatural killer cellsAcute tubular necrosisConnective tissue disordersPrimary genetic alterationIntensive care unitPostpartum coursePostpartum hemorrhageSevere preeclampsiaUncomplicated pregnanciesAnti-SSAUse of Intradialytic Parenteral Nutrition in Patients Undergoing Hemodialysis
Sarav M, Friedman A. Use of Intradialytic Parenteral Nutrition in Patients Undergoing Hemodialysis. Nutrition In Clinical Practice 2018, 33: 767-771. PMID: 30207411, DOI: 10.1002/ncp.10190.Peer-Reviewed Original ResearchProtein Energy Wasting in Hemodialysis Patients
Sarav M, Kovesdy C. Protein Energy Wasting in Hemodialysis Patients. Clinical Journal Of The American Society Of Nephrology 2018, 13: 1558-1560. PMID: 29954825, PMCID: PMC6218831, DOI: 10.2215/cjn.02150218.Peer-Reviewed Original Research
2017
Going Gluten Free: the History and Nutritional Implications of Today’s Most Popular Diet
Newberry C, McKnight L, Sarav M, Pickett-Blakely O. Going Gluten Free: the History and Nutritional Implications of Today’s Most Popular Diet. Current Gastroenterology Reports 2017, 19: 54. PMID: 28948465, DOI: 10.1007/s11894-017-0597-2.Peer-Reviewed Original ResearchProtein Intake in Chronic Kidney Disease
Sarav M, McKnight C, Newberry C. Protein Intake in Chronic Kidney Disease. Current Nutrition Reports 2017, 6: 257-260. DOI: 10.1007/s13668-017-0213-y.Peer-Reviewed Original ResearchChronic kidney diseasePoor nutritional statusKidney diseaseProtein intakeKeto-analogues of essential amino acidsNutritional statusChronic kidney disease patientsProgression of chronic kidney diseaseProtein-energy wastingLow protein intakeRecent FindingsRecent studiesSummaryIn summaryIndividual patient needsKidney functionComplex nutritional requirementsFindingsRecent studiesReviewThe purposePatientsPracticing nephrologistsAssociated with increasesAcute illnessHealthy adultsKeto analoguesIntakeDiseasePhysiology of Peritoneal Dialysis
Moreno A, Sarav M. Physiology of Peritoneal Dialysis. 2017, 7-15. DOI: 10.1007/978-3-319-52821-2_2.Peer-Reviewed Original ResearchSummary Points and Consensus Recommendations From the International Protein Summit
Hurt R, McClave S, Martindale R, Gautier J, Coss‐Bu J, Dickerson R, Heyland D, Hoffer L, Moore F, Morris C, Paddon‐Jones D, Patel J, Phillips S, Rugeles S, Sarav M, Weijs P, Wernerman J, Hamilton‐Reeves J, McClain C, Taylor B. Summary Points and Consensus Recommendations From the International Protein Summit. Nutrition In Clinical Practice 2017, 32: 142s-151s. PMID: 28388374, DOI: 10.1177/0884533617693610.Peer-Reviewed Original ResearchConceptsIntensive care unitPhase of critical illnessHigh nutritional riskInitial phase of critical illnessCritically ill patientsHealthcare professionalsMammalian target of rapamycinNutritional riskImproved insulin sensitivityDose of proteinClinical nutritionProtein goalsMuscle massNutrition therapyHigh doses of proteinClinical outcomesProtein administrationTarget of rapamycinBody protein homeostasisSummary PointsMeeting energy goalsHigh dosesNew protein synthesisProtein doseConsensus recommendationsAssessment of Protein Turnover in Health and Disease
Wernerman J, Morris C, Paddon‐Jones D, Sarav M. Assessment of Protein Turnover in Health and Disease. Nutrition In Clinical Practice 2017, 32: 15s-20s. PMID: 28388375, DOI: 10.1177/0884533617694611.Peer-Reviewed Original ResearchProtein Requirements for Critically Ill Patients With Renal and Liver Failure
Patel J, McClain C, Sarav M, Hamilton‐Reeves J, Hurt R. Protein Requirements for Critically Ill Patients With Renal and Liver Failure. Nutrition In Clinical Practice 2017, 32: 101s-111s. PMID: 28208022, DOI: 10.1177/0884533616687501.Peer-Reviewed Original ResearchConceptsDecompensated liver cirrhosisAcute kidney injuryAcute liver failureNegative nitrogen balanceMuscle wastingRenal replacement therapyCritically ill patientsRespiratory failureLiver dysfunctionReplacement therapyKidney injuryLiver failureLiver cirrhosisAmino acid lossesICU admissionIncreased riskOptimal protein supplementationSevere formIll patientsCritical illnessNitrogen balanceProtein abnormalitiesAssociated with proteolysisProtein requirementsAcid lossAcquired Amino Acid Deficiencies: A Focus on Arginine and Glutamine
Morris C, Hamilton‐Reeves J, Martindale R, Sarav M, Gautier J. Acquired Amino Acid Deficiencies: A Focus on Arginine and Glutamine. Nutrition In Clinical Practice 2017, 32: 30s-47s. PMID: 28388380, DOI: 10.1177/0884533617691250.Peer-Reviewed Original ResearchConceptsLow arginine bioavailabilityT cell dysfunctionAmino acidsSickle cell diseaseArginine bioavailabilityPulmonary hypertensionT cellsTherapeutic optionsConditionally essential amino acidsDeficiency syndromeCystic fibrosisEndothelial dysfunctionAcute asthmaAt-risk populationsCatabolic stateCell diseaseClinical scenariosAmino acid synthesisCritical illnessConditions of stressGastrointestinal disordersAcid deficiencyCardiovascular diseaseCatabolism of arginineSynthesized de novo
2015
Chronic kidney disease-mineral and bone disorder
Sprague S, Sarav M. Chronic kidney disease-mineral and bone disorder. 2015, 916-922. DOI: 10.1093/med/9780199592548.003.0115.Peer-Reviewed Original Research